Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 19 of the 54 sources its claims cite were checked for support.

Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study

Open access
Michel, Alexandra, Dorval, Michel, Chiquette, Jocelyne, Savard, Josée · 2024 · Hereditary Cancer in Clinical Practice

Abstract

Background: Fear of cancer recurrence (FCR) affects virtually all patients who have been treated for cancer, to varying degrees. Breast cancer survivors who carry a BRCA1 or BRCA2 gene mutation are at high risk of cancer recurrence. No study has yet assessed FCR specifically in this population. Objectives: This cross-sectional study, conducted in women who were treated for breast cancer and carrying a BRCA1/2 mutation, aimed to: (1) assess the mean level of FCR and estimate the proportion of patients with clinical levels of FCR; (2) examine the relationships between FCR and selected psychological variables (e.g., avoidance, intolerance to uncertainty) and quality of life; (3) explore whether FCR levels vary as a function of the past preventive treatment received; and (4) to assess the associations between FCR and the presence of decisional conflict or regret regarding the various preventive options. Method: Participants were recruited through an e-mail sent to an oncogenetic network mailing list (Réseau ROSE). Participants were asked to complete a battery of questionnaires online assessing FCR and other psychological and quality of life variables. Results: A total of 89 women completed the survey. Most participants had undergone a preventive mastectomy (62.9%) and a preventive salpingo-oophorectomy (75.3%) at the time of the study. The mean Fear of Cancer Recurrence Inventory-severity score was 16.8, which exceeds the clinical cut-off score of 13, and 70.8% of the participants showed a clinical level of FCR. FCR was significantly associated with higher levels of anxiety and depression, and higher avoidance and intolerance of uncertainty, but not with quality of life. No significant difference was observed on the total FCR score between women who had received preventive surgery (mastectomy and/or salpingo-oophorectomy) and those considering it, and those not considering it. The association was significant between higher FRC scores and greater decisional conflicts and regrets about choosing to undergo preventive surgery. Conclusion: These data suggest that FCR is a significant problem for breast cancer survivors carrying a BRCA1/2 genetic mutation, even after undergoing a prophylactic surgery. This highlights the importance of providing these women with specific psychological intervention focusing on FCR. © The Author(s) 2024.

Overview

CoChat Summary

## TL;DR

This cross-sectional study found that fear of cancer recurrence (FCR) was highly prevalent among 89 breast cancer survivors carrying a BRCA1/2 mutation, even though most had already undergone preventive surgery. Higher FCR was linked to anxiety, depression, intolerance of uncertainty, avoidance, and decisional conflict/regret, but not to quality of life.

## Key findings

  • Among 89 participants, the mean Fear of Cancer Recurrence Inventory-severity score was 16.8, above the clinical cut-off of 13, and 70.8% showed a clinical level of FCR.
  • FCR was significantly associated with higher anxiety, depression, avoidance, and intolerance of uncertainty; correlations with the total FCRI score included anxiety (r = 0.694), depression (r = 0.423), and intolerance of uncertainty (r = 0.430).
  • FCR was not significantly associated with quality of life (r = -0.171, p = 0.128).
  • Past preventive treatment was not significantly related to FCR: no between-group differences were found across women who had mastectomy only, salpingo-oophorectomy only, both procedures, or no procedure; FCR was also not significantly related to time since the most recent preventive surgery.
  • Higher FCR was significantly associated with greater decisional conflict and decisional regret; for the total FCRI score, r = 0.235 with decisional conflict and r = 0.337 with regret.

## Methods

  • Cross-sectional survey of women aged 18–80 treated for non-metastatic breast or ovarian cancer, carrying a BRCA1 or BRCA2 mutation, and able to read French; women on active cancer treatment other than adjuvant hormone therapy were excluded.
  • Recruitment was through an email announcement sent to the ROSE oncogenetic network mailing list in Quebec, Canada, between October 9, 2020 and May 10, 2021; 89 women completed the survey, and all available data were used in analyses.
  • Participants completed online questionnaires measuring FCR, anxiety and depression (HADS), intolerance of uncertainty (IUS), trauma-related symptoms (IES), quality of life (QLQ-C30), decisional conflict (DCS), and decisional regret (DRS); analyses included descriptive statistics, multivariable linear models, correlations, and ANOVAs.

## Limitations

  • The paper states that it used a convenience sample because there was no population-based registry, so selection bias is possible and generalizability to the full population is uncertain.
  • The study was cross-sectional, so it could not assess change over time or make causal inferences.
  • The paper states that statistical power was limited for some comparative analyses because of sample size; additionally, recruitment occurred during the second and third COVID-19 waves, which may have temporarily increased anxiety about medical care.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1186/s13053-024-00285-5

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Verification

Claims the paper makes

14 Valid · 0 Not valid · 14 Not checked · 60 Own results and interpretations

54 more claims · 3 with their cited sources checked

Create a free account to see all 88 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 16
  • Probably not a substantial claim. 20

Create a free account to see these claims.

Citations

Cites

Show all 82 references

Research works printed but not linked: 1

  1. SPSS I. Statistics for Windows (Version 26.0)[Computer Software]. Armonk, NY: IBM Corp; 2019.

Cited by

See all 3

Metadata

Authors
Michel, A., Dorval, M., Chiquette, J., & Savard, J.
Affiliations
Hôpital de l'Enfant-Jésus (CA)
Corresponding author
Savard, Josée
Venue
Hereditary Cancer in Clinical Practice
Published
2024-08-27
Volume
22
Issue
1
Pages
16-16
ISSN
  • 1731-2302 (ISSN-L)
  • 1897-4287
OpenAlex
W4401905534
Cited by
3
References
82
Citations by year
2026: 1 · 2025: 1 · 2024: 1
FWCI
0.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Hereditary Cancer in Clinical Practice (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
CHU de Québec-Université Laval Foundation (4225)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Women's cancer prevention and management
Keywords
fear of cancer recurrence, breast cancer survivors, BRCA1 mutation, BRCA2 mutation, hereditary breast cancer, salpingo-oophorectomy, decisional conflict, regret, avoidance, intolerance of uncertainty, anxiety, depression, quality of life, psychological intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study. https://app.cochat.ai/papers/10.1186/s13053-024-00285-5
The paper
Michel, A., Dorval, M., Chiquette, J., & Savard, J. (2024). Fear of cancer recurrence in breast cancer survivors carrying a BRCA1 or 2 genetic mutation : a cross-sectional study. Hereditary Cancer in Clinical Practice. https://doi.org/10.1186/s13053-024-00285-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.